Abstract
Clinical trials have the potential to extend and possibly save lives. But they are not readily accessible to patients with metastatic cancer. They place undue burdens on patients, employ restrictive eligibility requirements, and do not reflect the perspective of the metastatic population, making it difficult to impossible for patients to participate in appropriate, convenient trials in a timely manner. Clinical trials are often the last resort for metastatic patients, who have exhausted all “standard of care” options. Yet, for that very reason, metastatic patients are typically excluded from most clinical trials.
Citation Format: April Knowles. [Advocate Abstract:] Metastatic patients and clinical trials [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr B91.
RSS Feeds